Metformin promotes induction of lipoprotein lipase in skeletal muscle through activation of adenosine monophosphate-activated protein kinase

Metabolism: Clinical and Experimental

Volumn 58, Issue 10, 2009, Pages 1408-1414

  Ohira, Masahiro ^a   Miyashita, Yoh ^a   Murano, Takeyoshi ^b   Watanabe, Fusako ^b   Shirai, Kohji ^b  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b Toho University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOIMIDAZOLE 4 CARBOXAMIDE RIBONUCLEOSIDE; ADENOSINE PHOSPHATE; LIPOPROTEIN LIPASE; MESSENGER RNA; METFORMIN; PROTEIN KINASE; RIBONUCLEOSIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL LINE; DRUG EFFECT; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WESTERN BLOTTING;

3T3 CELLS; ADIPOCYTES; ANIMALS; BLOTTING, WESTERN; CLONING, MOLECULAR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; HYPOGLYCEMIC AGENTS; LIPOPROTEIN LIPASE; METFORMIN; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 70249116084     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.04.024     Document Type: Article

References (23)

1. Bailey C.J., and Turner R.C. Metformin. N Eng J Med 334 (1966) 574-579
2. Inzucchi S.E., Maggs D.G., Spollet G.R., Page S.L., Rife F.S., Walton V., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Eng J Med 338 (1998) 867-872
3. Phillips S.A., Ciaraldi T.P., Kong A.P.S., Bandukwala R., Aroda V., Carter L., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
4. He G., Pedersen S.B., Bruun J.M., Lihn A.S., and Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res 35 (2003) 18-23
5. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in the mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
6. Reaven G.M., Johnston P., Hollenbeck C.B., Skowronski R., Zhang J.C., Goldfine I.D., et al. Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74 (1992) 1020-1026
7. Totsuka M., Miyashita Y., Ito Y., Watanabe H., Murano T., and Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153 (2000) 175-179
8. Shirai K., Itoh I., Sasaki H., Totsuka M., Murano T., Watanabe H., et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pr 46 (1999) 35-41
9. Ohira M., Miyashita Y., Ebisuno M., Saiki A., Endo K., Koide N., et al. Effect of metformin on lipoprotein lipase mass in preheparin serum, and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pr 78 (2007) 34-41
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 103 (1998) 854-865
11. Statton I.M., Adler A.I., Neil H.A., Matthews D.R., Manly S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
12. Velazquez E.M., Mendoza S.G., Wang P., and Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46 (1997) 454-457
13. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Thèroud P., Legrand A., and Beardeux J.L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54 (2005) 829-834
14. Malloy M.J., and Kane J.P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 47 (2001) 111-136
15. Hardie D.G., and Hawley S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bio Essays 23 (2001) 1112-1119
16. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
17. An D., Pulinilkunnil T., Qi D., Ghosh S., Abrahani A., and Rodrigues B. The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288 (2005) 246-253
18. Huypens P., Quartier E., Pipeleers D., and Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 518 (2005) 90-95
19. Kim S.J., Nian C., and McIntosh C.H. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 32 (2007) 557-566
20. Kim S.J., Nian C., and McIntosh C.H. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282 (2007) 34139-34147
21. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15 (1996) 5336-5348
22. Frøsig C., Jørgensen S.B., Hardie D.G., Richter E.A., and Wojtaszewski J.F. 5′-AMP-activated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle. Am J Physiol Endocrinol Metab 286 (2004) E411-E417
23. Takekoshi K., Fukuhara M., Quin Z., Nissato S., Isobe K., Kawakami Y., et al. Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit expression in rat visceral adipose tissue and liver. Metabolism 55 (2006) 1122-1128